α4-integrin receptor desaturation and disease activity return after natalizumab cessation
Tobias Derfuss, John M Kovarik, Ludwig Kappos, Marina Savelieva, Richa Chhabra, Avinash Thakur, Ying Zhang, Heinz Wiendl, Davorka Tomic, Tobias Derfuss, John M Kovarik, Ludwig Kappos, Marina Savelieva, Richa Chhabra, Avinash Thakur, Ying Zhang, Heinz Wiendl, Davorka Tomic
Abstract
Objective: To describe the time course of α4-integrin receptor desaturation and disease activity return in patients with relapsing-remitting MS who discontinued natalizumab and to investigate baseline and on-study predictors for the recurrence of disease activity.
Methods: In the course of TOFINGO, a 32-week, patient- and rater-blinded multicenter, parallel-group study, we performed MRI, counted relapses, and measured α4-integrin receptor occupancy (RO) at baseline and 8, 12, 16, 20, and 24 weeks. The relationship between RO and total number of new T1 gadolinium-enhancing (Gd+) lesions was modeled using Poisson linear regression.
Results: Patients (N = 142) were randomized (1:1:1) to 8-, 12-, or 16-week washout (WO) groups. At randomization, the median RO in the 8-, 12-, and 16-week WO groups was 94.5%, 92.4%, and 90.9%, which declined to 79.8%, 30.7%, and 8.7% after 8, 12, and 16 weeks of WO, respectively. The percentage of patients with new T1 Gd+ lesions increased with longer WO period before commencing fingolimod: 2.1% (8 weeks), 9.1% (12 weeks), and 50.0% (16 weeks). Overall, 71% of patients with first relapse between weeks 6 and 18 had RO values below the time-matched population median. Higher T2 lesion volume (LV) at baseline predicted a higher number of new T1 Gd+ lesions.
Conclusions: A faster decline in natalizumab RO, longer WO period, and higher T2 LV at baseline were associated with an increased risk for return of inflammatory disease activity. These results provide a mechanistic rationale and, together with the main outcomes of the TOFINGO study, support initiation of fingolimod within 8 weeks of natalizumab discontinuation.
Clinicaltrialsgov identifier: NCT01499667.
Figures
References
- Bloomgren G, Richman S, Hotermans C, et al. . Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870–1880.
- Rasenack M, Derfuss T. Disease activity return after natalizumab cessation in multiple sclerosis. Expert Rev Neurother 2016;16:587–594.
- Klotz L, Grutzke B, Eveslage M, et al. . Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). BMC Neurol 2015;15:96.
- Kappos L, Radue EW, Comi G, et al. . Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology 2015;85:29–39.
- Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.
- Jokubaitis VG, Li V, Kalincik T, et al. . Fingolimod after natalizumab and the risk of short-term relapse. Neurology 2014;82:1204–1211.
- Naegelin Y, Rasenack M, Blatti C, et al. . Switching from natalizumab to fingolimod: recurrence of disease activity is closely related to duration of wash out and alpha-4 integrin desaturation—a prospective study in RRMS. Mult Scler J 2015;21(11 suppl):556–557.
- Cohen M, Maillart E, Tourbah A, et al. . Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol 2014;71:436–441.
- Fox RJ, Cree BA, De Seze J, et al. . MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014;82:1491–1498.
- Naegelin Y, Rasenack M, Sanderson N, et al. . An observational study evaluating disease control, safety, and immunological changes in patients with relapsing remitting multiple sclerosis switching from previous treatment with natalizumab to fingolimod (SWITCH-UHBS). Mult Scler J 2013;19(11 Suppl):460.
Source: PubMed